Objective To investigate the relationship between clinical efficacy and lymphocyte subset variation in the treatment of middle and late stage hepatocellular carcinoma(HCC)undergoing initial transarterial chemoembolization(TACE).Methods A retrospective analysis was conducted on the clinical data of 33 patients with middle and late stage HCC who received initial TACE treatment.Lymphocyte subsets were measured before treatment and one month after treatment.Short-term efficacy was evaluated based on the modified response evaluation criteria in solid tumors(mRECIST),and then the patients were divided into remission group[18 cases,including complete remission(CR)and partial remission(PR)]and non-remission group[15 cases,including stable disease(SD)and progressive disease(PD)].The characteristics of lymphocyte subset variation characteristics before and after treatment were compared between the two groups.Results In the remission group,the absolute count and percentage of CD8+cells significantly increased,while the CD4/CD8 ratio and the percentage of CD19+cells significantly decreased after treatment(P＜0.05).Conversely,in the non-remission group,the percentage of CD8+cells significantly decreased,while the CD4/CD8 ratio and the percentage of CD19+cells significantly increased after treatment(P＜0.05).Significant differences were observed between the two groups in the changes of CD8+cells percentage,CD4/CD8 ratio,and CD19+cells percentage before and after treatment(P＜0.05).Conclusion The CD8+cells percentage,CD4/CD8 ratio,and CD19+cells percentage may serve as potential molecular markers for predicting treatment outcomes in HCC patients undergoing TACE.A decrease in the CD8+cells percentage accompanied by an increase in the CD4/CD8 ratio and CD19+cells percentage after the initial TACE treatment may indicate poor therapeutic outcomes.Timely adjustment of individualized treatment plans is recommended to improve patient prognosis.

Objective To investigate the relationship between clinical efficacy and lymphocyte subset variation in the treatment of middle and late stage hepatocellular carcinoma(HCC)undergoing initial transarterial chemoembolization(TACE).Methods A retrospective analysis was conducted on the clinical data of 33 patients with middle and late stage HCC who received initial TACE treatment.Lymphocyte subsets were measured before treatment and one month after treatment.Short-term efficacy was evaluated based on the modified response evaluation criteria in solid tumors(mRECIST),and then the patients were divided into remission group[18 cases,including complete remission(CR)and partial remission(PR)]and non-remission group[15 cases,including stable disease(SD)and progressive disease(PD)].The characteristics of lymphocyte subset variation characteristics before and after treatment were compared between the two groups.Results In the remission group,the absolute count and percentage of CD8+cells significantly increased,while the CD4/CD8 ratio and the percentage of CD19+cells significantly decreased after treatment(P＜0.05).Conversely,in the non-remission group,the percentage of CD8+cells significantly decreased,while the CD4/CD8 ratio and the percentage of CD19+cells significantly increased after treatment(P＜0.05).Significant differences were observed between the two groups in the changes of CD8+cells percentage,CD4/CD8 ratio,and CD19+cells percentage before and after treatment(P＜0.05).Conclusion The CD8+cells percentage,CD4/CD8 ratio,and CD19+cells percentage may serve as potential molecular markers for predicting treatment outcomes in HCC patients undergoing TACE.A decrease in the CD8+cells percentage accompanied by an increase in the CD4/CD8 ratio and CD19+cells percentage after the initial TACE treatment may indicate poor therapeutic outcomes.Timely adjustment of individualized treatment plans is recommended to improve patient prognosis.